Inquiry Basket
Loading ......
Porcine reproductive and respiratory syndrome, widely abbreviated as PRRS and caused by the porcine reproductive and respiratory syndrome virus (PRRSV), has been one of the most consequential infectious diseases of swine since it was first recognized in the late 1980s. More than three decades later, the virus remains a moving target for veterinarians, producers, and diagnostic researchers alike. This article examines why the disease is so persistent, what it costs the global pork sector, how it presents in affected herds, and where modern serology, molecular testing, and research-grade reagents fit into sustainable control.
The economic weight of PRRSV is difficult to overstate. Research has estimated that PRRSV attributable productivity losses reached roughly 1.2 billion US dollars per year, a striking increase from the 664 million dollars estimated for 2013. Breeding-herd losses accounted for about 381 million dollars annually, while the growing-pig phase — from weaning to market — absorbed the large majority at approximately 819 million dollars. Notably, around two-thirds of the total cost originated in the wean-to-market segment, where PRRSV undermines daily gain, feed efficiency, and survival.
These figures matter because they reframe PRRSV from a clinical nuisance into a structural constraint on pork profitability. When a single pathogen can remove more than one billion dollars from a national supply chain each year, investments in surveillance, biosecurity, and well-characterized diagnostic reagents stop being optional and become core operating costs. For researchers supplying antibodies, recombinant antigens, and assay components, the implication is clear: demand is driven not by curiosity alone but by the relentless economics of disease control.
Figure 1. Pathways from sow farms in their three potential PRRSV infection phases to wean-to-finish (WtF) closeouts in their three potential infection phases. (Source: Thoma GJ, et al. 2025)
PRRSV is endemic in most pig-producing regions and is characterized by a frustrating capacity to return. Once introduced, the virus can establish persistent infection in a herd, circulate silently in subpopulations, and re-emerge when immunity wanes or a new variant enters. The American Association of Swine Veterinarians herd-classification system — negative or provisionally negative, positive stable, and positive unstable — exists precisely because status is fluid rather than fixed. A farm that reaches a virus-free state can lose it within months; published surveillance data indicate that among breeding herds achieving a naive status, the median duration before a new wild-type introduction was well under two years.
Control is not a one-time event but a continuous process of monitoring, vaccination or exposure management, and rapid response when status changes. The virus's RNA genome, replicated by an error-prone polymerase without proofreading, generates the diversity that keeps the cycle turning.
Clinically, PRRSV earns its name through two principal syndromes. In breeding animals, the reproductive form produces late-term abortions, increased numbers of stillborn and mummified piglets, weak-born piglets, and delayed return to estrus. The "porcine reproductive respiratory syndrome" framing captures this duality, but the respiratory dimension is equally damaging. In nursery and grow-finish pigs, PRRSV infection precipitates interstitial pneumonia, dyspnea, lethargy, and elevated mortality, often compounded by secondary bacterial invaders such as Streptococcus suis or Mycoplasma hyopneumoniae.
Young piglets are especially vulnerable: viremia can persist for weeks, and infected animals may shed virus through oral fluids, nasal secretions, and semen, sustaining transmission within and between groups. The disease's immunosuppressive character means that what begins as a PRRSV event frequently cascades into multi-pathogen respiratory disease complexes that are far harder to untangle.
Figure 2. Conceptual summary of the impacts of porcine reproductive and respiratory syndrome (PRRS) on herd health, productivity, antimicrobial use, and animal welfare. (Source: Khan S, et al. 2026)
If PRRSV is so costly, why has it not been solved? The central obstacle is viral diversity combined with imperfect immunity. PRRSV is divided into two distinct species, PRRSV-1 (European-like) and PRRSV-2 (North American-like), which share only about 60 percent nucleotide identity and do not cross-protect. Within PRRSV-2 alone, multiple genetic lineages circulate, and field strains differ enough that a vaccine based on one strain often provides only partial heterologous protection.
Modified live virus (MLV) vaccines are the workhorse of immunization programs and can reduce the severity and duration of outbreaks. Yet a growing body of literature describes them as "leaky": they replicate, induce viremia and shedding, and fail to deliver sterilizing immunity. Heterologous cross-protection is inconsistent, and there are documented concerns about reversion to virulence and recombination between vaccine and field strains. These limitations mean a "PRRS vaccine" query rarely leads to a single satisfying answer, because no current vaccine confers the broad, durable protection that producers want against the full spectrum of circulating variants.
Given that vaccines cannot alone eliminate the virus, surveillance becomes the backbone of any credible control effort. Two diagnostic pillars dominate. The first is serology, most often an enzyme-linked immunosorbent assay (ELISA) measuring antibodies against PRRSV, frequently directed at the conserved nucleocapsid (N) protein. Serology is inexpensive, scalable, and ideal for mapping exposure across a herd or region. A recombinant PRRSV N-protein antigen expressed in bacteria provides a stable, batch-consistent coating reagent that supports population-level screening without relying on live virus.
The second pillar is molecular detection, typically quantitative reverse-transcription PCR (qRT-PCR) targeting conserved regions such as ORF7. This approach confirms active infection and, when paired with sequencing, distinguishes vaccine-like from wild-type viruses and assigns lineage. A practical advance has been the use of oral-fluid sampling — collectively gathered from pens or litters — which is welfare-friendly and cost-effective. Studies comparing serum and oral fluid in suckling piglets found that collective oral-fluid PCR detected virus at rates comparable to blood sampling, and that pooling family oral fluids remains a valid strategy under cost constraints, provided sampling captures as many litters as possible to preserve detection probability.
Behind every field test sit the research reagents that make it possible. Recombinant PRRSV N-protein antigens are central to competitive and indirect ELISAs, while research-grade anti-PRRSV antibodies — including monoclonal and nanobody-derived reagents — enable the capture and detection steps that give those assays their specificity. A nanobody-based competitive ELISA targeting the PRRSV-2 N protein, for example, demonstrated genotype-specific detection with high concordance against established kits, illustrating how engineered reagents can sharpen differentiation between PRRSV-1 and PRRSV-2 infections.
For surveillance scientists, the value of standardized reagents is twofold. First, they allow longitudinal comparisons across years and laboratories, which is essential for tracking whether a regional control program is actually reducing wild-type prevalence. Second, they support the development of novel formats — lateral-flow devices, luciferase immunoprecipitation systems, and multiplexed serological panels — that could one day resolve co-infections and vaccine-versus-field exposure in a single run. The nucleocapsid protein, being relatively conserved, remains the most practical anchor for these tools, even as envelope glycoproteins such as GP5 attract attention for their role in neutralizing responses.
Taken together, the evidence points to a disease that is biologically evasive and economically immovable, yet increasingly manageable through disciplined surveillance. Serology and qPCR, anchored by well-characterized recombinant antigens and antibodies, give producers the situational awareness required to act early. As viral diversity continues to expand, the research community's task is to keep those reagents one step ahead of the field strains they must detect.
References
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| PRRSV | DAG-WT1143 | Recombinant PRRSV GP5 Protein [His] | E. coli | His | ELISA, WB | Inquiry |
| DAGC754 | Recombinant PRRSV GP5 Protein [His] | Baculovirus | His | ELISA | Inquiry | |
| DAG-WT806 | Recombinant PRRSV N-NSP7 Fusion Antigen | E. coli | TBD | Immunoassays | Inquiry | |
| DAGA-2015 | Recombinant HP-PRRSV Nucleocapsid Protein [His] | E. coli | His | ELISA, WB | Inquiry | |
| DAGA-2016 | HP-PRRSV nsp7 (aa 2051-2308) [His] | E. coli | His | ELISA, WB | Inquiry | |
| DAG-WT7302 | Inactivated PRRSV (Strain TJF-F92) Culture Fluid | N/A | N/A | Control | Inquiry | |
| PRRSV NP | DAGC-55249 | Recombinant PRRSV-2 Nucleocapsid Protein [His] | E. coli | His | ELISA, WB | Inquiry |
| DAGC-55251 | Recombinant PRRSV-1 Nucleocapsid Protein [His] | E. coli | His | ELISA, WB | Inquiry | |
| DAGC-55252 | Recombinant PRRSV-2 Nucleocapsid Protein [GST] | E. coli | GST | WB | Inquiry |
Loading ......
